Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Taxes (2024 - 2025)

Adma Biologics (ADMA) has disclosed Current Taxes for 2 consecutive years, with $8.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Taxes rose 147.52% year-over-year to $8.6 million, compared with a TTM value of $8.6 million through Dec 2025, up 147.52%, and an annual FY2025 reading of $8.6 million, up 147.52% over the prior year.
  • Current Taxes was $8.6 million for Q4 2025 at Adma Biologics, up from $2.8 million in the prior quarter.
  • Across five years, Current Taxes topped out at $8.6 million in Q4 2025 and bottomed at $2.7 million in Q2 2025.